Alzheimer ‘s
Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry
Sanofi Licenses ADEL’s Tau-Targeting Alzheimer’s Drug for $1.04 Billion Deal Including $80M Upfront
Sanofi; ADEL; Alzheimer’s; tau-targeting; licensing deal; biotech
Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India
Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune
Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases
Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates
FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting
FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.
Biogen Expands Leqembi Field Force and Launches Omnichannel Campaigns for Next Phase
Biogen, Leqembi, field force, expansion, omnichannel campaigns, launch phase, Alzheimer’s treatment